Build Your Comparison

Side-by-side financial analysis
KLTO logo
KLTO
ATHA logo
ATHA
KO logo
KO
SAVA logo
SAVA
ACIU logo
ACIU
Try popular comparisons:

Stock Comparison

KLTO vs ATHA vs KO vs SAVA vs ACIU

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
KLTO
Klotho Neurosciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-59.1%
ATHA
Athira Pharma, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$17M
5Y Perf.-84.6%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+12.5%
SAVA
Cassava Sciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$64M
5Y Perf.-52.3%
ACIU
AC Immune S.A.

Biotechnology

HealthcareNASDAQ • CH
Market Cap$235M
5Y Perf.-9.3%

KLTO vs ATHA vs KO vs SAVA vs ACIU — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
KLTO logoKLTO
ATHA logoATHA
KO logoKO
SAVA logoSAVA
ACIU logoACIU
IndustryBiotechnologyBiotechnologyBeverages - Non-AlcoholicBiotechnologyBiotechnology
Market Cap$7M$17M$355.61B$64M$235M
Revenue (TTM)$0.00$0.00$49.28B$0.00$4M
Net Income (TTM)$-11M$-129M$13.70B$-106M$-70M
Gross Margin61.7%100.0%
Operating Margin29.3%-19.3%
Forward P/E25.3x
Total Debt$272K$803K$45.49B$0.00$5M
Cash & Equiv.$64K$69M$10.27B$129M$27M

KLTO vs ATHA vs KO vs SAVA vs ACIULong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

KLTO
ATHA
KO
SAVA
ACIU
StockAug 24Mar 26Return
Klotho Neuroscience… (KLTO)10040.9-59.1%
Athira Pharma, Inc. (ATHA)10015.4-84.6%
The Coca-Cola Compa… (KO)100112.5+12.5%
Cassava Sciences, I… (SAVA)10047.7-52.3%
AC Immune S.A. (ACIU)10090.7-9.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: KLTO vs ATHA vs KO vs SAVA vs ACIU

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 4 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Athira Pharma, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Healthcare Pick

KLTO plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ATHA
Athira Pharma, Inc.
The Income Pick

ATHA is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • beta 1.37
  • Lower volatility, beta 1.37, Low D/E 2.9%, current ratio 1.88x
  • Beta 1.37, current ratio 1.88x
  • Beta 1.37 vs SAVA's 1.92
Best for: income & stability and sleep-well-at-night
KO
The Coca-Cola Company
The Growth Play

KO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
  • 121.1% 10Y total return vs KLTO's -63.0%
  • 1.9% revenue growth vs KLTO's -49.0%
  • 27.8% margin vs ACIU's -19.7%
Best for: growth exposure and long-term compounding
SAVA
Cassava Sciences, Inc.
The Healthcare Pick

SAVA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ACIU
AC Immune S.A.
The Healthcare Pick

Among these 5 stocks, ACIU doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthKO logoKO1.9% revenue growth vs KLTO's -49.0%
Quality / MarginsKO logoKO27.8% margin vs ACIU's -19.7%
Stability / SafetyATHA logoATHABeta 1.37 vs SAVA's 1.92
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)ATHA logoATHA+40.0% vs KLTO's -81.0%
Efficiency (ROA)KO logoKO13.1% ROA vs ATHA's -225.7%

KLTO vs ATHA vs KO vs SAVA vs ACIU — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

KLTOKlotho Neurosciences, Inc.

Segment breakdown not available.

ATHAAthira Pharma, Inc.

Segment breakdown not available.

KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
SAVACassava Sciences, Inc.

Segment breakdown not available.

ACIUAC Immune S.A.

Segment breakdown not available.

KLTO vs ATHA vs KO vs SAVA vs ACIU — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGACIU

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 4 of 6 comparable metrics.

KO and SAVA operate at a comparable scale, with $49.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ACIU's -19.7%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
RevenueTrailing 12 months$0$0$49.3B$0$4M
EBITDAEarnings before interest/tax-$8M-$110M$15.5B-$110M-$67M
Net IncomeAfter-tax profit-$11M-$129M$13.7B-$106M-$70M
Free Cash FlowCash after capex-$6M-$52M$12.6B-$84M-$70M
Gross MarginGross profit ÷ Revenue+61.7%+100.0%
Operating MarginEBIT ÷ Revenue+29.3%-19.3%
Net MarginNet income ÷ Revenue+27.8%-19.7%
FCF MarginFCF ÷ Revenue+25.5%-19.6%
Rev. Growth (YoY)Latest quarter vs prior year+12.1%-70.3%
EPS Growth (YoY)Latest quarter vs prior year+72.9%+24.8%+18.2%+62.1%+6.7%
KO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ATHA and KO and ACIU each lead in 1 of 3 comparable metrics.
MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
Market CapShares × price$7M$17M$355.6B$64M$235M
Enterprise ValueMkt cap + debt − cash$8M-$30M$390.8B-$65M$207M
Trailing P/EPrice ÷ TTM EPS-1.19x-0.17x27.18x-2.54x-2.63x
Forward P/EPrice ÷ next-FY EPS est.25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue7.42x52.43x
Price / BookPrice ÷ Book value/share6.19x0.37x10.40x0.42x4.13x
Price / FCFMarket cap ÷ FCF67.15x
Evenly matched — ATHA and KO and ACIU each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-4 for ATHA. ATHA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs ACIU's 2/9, reflecting strong financial health.

MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
ROE (TTM)Return on equity-113.7%-3.8%+41.1%-95.8%-101.6%
ROA (TTM)Return on assets-112.1%-2.3%+13.1%-75.3%-38.7%
ROICReturn on invested capital-2.4%+15.8%-6.3%-99.2%
ROCEReturn on capital employed-6.2%-2.3%+17.3%-99.9%-72.6%
Piotroski ScoreFundamental quality 0–942722
Debt / EquityFinancial leverage0.23x0.03x1.33x0.10x
Net DebtTotal debt minus cash$208,012-$68M$35.2B-$129M-$22M
Cash & Equiv.Liquid assets$63,741$69M$10.3B$129M$27M
Total DebtShort + long-term debt$271,753$803,000$45.5B$0$5M
Interest CoverageEBIT ÷ Interest expense-1.98x10.70x-482.85x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $224 for ATHA. Over the past 12 months, ATHA leads with a +40.0% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs ATHA's -48.9% — a key indicator of consistent wealth creation.

MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
YTD ReturnYear-to-date+19.1%-37.6%+20.3%-36.8%-31.3%
1-Year ReturnPast 12 months-81.0%+40.0%+17.2%-37.7%+11.6%
3-Year ReturnCumulative with dividends-63.0%-86.6%+47.0%-62.5%+8.5%
5-Year ReturnCumulative with dividends-63.0%-97.8%+65.6%-87.8%-68.8%
10-Year ReturnCumulative with dividends-63.0%-97.5%+121.1%-38.0%-85.2%
CAGR (3Y)Annualised 3-year return-28.2%-48.9%+13.7%-27.9%+2.7%
KO leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
Beta (5Y)Sensitivity to S&P 5001.91x1.37x-0.20x1.92x1.69x
52-Week HighHighest price in past year$2.45$8.36$84.04$4.98$4.00
52-Week LowLowest price in past year$0.21$2.85$65.35$1.27$1.65
% of 52W HighCurrent price vs 52-week peak+15.6%+51.9%+98.3%+26.5%+57.8%
RSI (14)Momentum oscillator 0–10061.938.460.642.734.7
Avg Volume (50D)Average daily shares traded95K46K12.7M134K294K
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: KO as "Buy", SAVA as "Buy", ACIU as "Buy". Consensus price targets imply 203.0% upside for ACIU (target: $7) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricKLTO logoKLTOKlotho Neuroscien…ATHA logoATHAAthira Pharma, In…KO logoKOThe Coca-Cola Com…SAVA logoSAVACassava Sciences,…ACIU logoACIUAC Immune S.A.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$86.13$7.00
# AnalystsCovering analysts48129
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises560
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap+1.6%0.0%+0.2%0.0%0.0%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 5 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.

Best OverallThe Coca-Cola Company (KO)Leads 5 of 6 categories
Loading custom metrics...

KLTO vs ATHA vs KO vs SAVA vs ACIU: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is KLTO or ATHA or KO or SAVA or ACIU a better buy right now?

For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.

9% revenue growth year-over-year, versus -86. 9% for AC Immune S. A. (ACIU). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate The Coca-Cola Company (KO) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — KLTO or ATHA or KO or SAVA or ACIU?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -97. 8% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: KO returned +121. 1% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — KLTO or ATHA or KO or SAVA or ACIU?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately -1060% more volatile than KO relative to the S&P 500. On balance sheet safety, Athira Pharma, Inc. (ATHA) carries a lower debt/equity ratio of 3% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

04

Which is growing faster — KLTO or ATHA or KO or SAVA or ACIU?

By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.

9% versus -86. 9% for AC Immune S. A. (ACIU). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — KLTO or ATHA or KO or SAVA or ACIU?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is KLTO or ATHA or KO or SAVA or ACIU more undervalued right now?

Analyst consensus price targets imply the most upside for ACIU: 203.

0% to $7. 00.

07

Which pays a better dividend — KLTO or ATHA or KO or SAVA or ACIU?

In this comparison, KO (2.

5% yield) pays a dividend. KLTO, ATHA, SAVA, ACIU do not pay a meaningful dividend and should not be held primarily for income.

08

Is KLTO or ATHA or KO or SAVA or ACIU better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between KLTO and ATHA and KO and SAVA and ACIU?

These companies operate in different sectors (KLTO (Healthcare) and ATHA (Healthcare) and KO (Consumer Defensive) and SAVA (Healthcare) and ACIU (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while KLTO, ATHA, SAVA, ACIU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.